Certain [chemotherapy drugs](href), such as anthracyclines and trastuzumab, can cause direct damage to the heart muscle, leading to a condition known as chemotherapy-induced cardiotoxicity. Elevated troponin levels can serve as an early marker of this damage, allowing for timely intervention to prevent irreversible cardiac damage. Monitoring troponins in cancer patients undergoing chemotherapy can help in adjusting treatment protocols to minimize cardiac risks.
